Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 312,029
  • Shares Outstanding, K 82,113
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,510 K
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.49
Trade AVXL with:

Options Overview Details

View History
  • Implied Volatility 121.85% ( +10.40%)
  • Historical Volatility 62.62%
  • IV Percentile 70%
  • IV Rank 31.30%
  • IV High 388.12% on 04/04/24
  • IV Low 0.51% on 07/03/23
  • Put/Call Vol Ratio 0.53
  • Today's Volume 742
  • Volume Avg (30-Day) 616
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 66,263
  • Open Int (30-Day) 66,431

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.60 +5.00%
on 04/19/24
5.29 -28.54%
on 03/21/24
-1.06 (-21.90%)
since 03/19/24
3-Month
3.60 +5.00%
on 04/19/24
6.90 -45.21%
on 01/26/24
-2.27 (-37.52%)
since 01/19/24
52-Week
3.60 +5.00%
on 04/19/24
10.45 -63.83%
on 12/19/23
-4.41 (-53.85%)
since 04/19/23

Most Recent Stories

More News
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

AVXL : 3.78 (-0.53%)
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot

Anavex Life Sciences: Fiscal Q4 Earnings Snapshot

AVXL : 3.78 (-0.53%)
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot

Anavex Life Sciences: Fiscal Q3 Earnings Snapshot

AVXL : 3.78 (-0.53%)
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot

Anavex Life Sciences: Fiscal Q2 Earnings Snapshot

AVXL : 3.78 (-0.53%)
Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio

Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.

ADMA : 6.27 (+1.13%)
ACAD : 16.82 (-1.46%)
AVXL : 3.78 (-0.53%)
APTX : 0.0960 (+3.11%)
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value

The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.

JPM : 185.80 (+2.51%)
AVXL : 3.78 (-0.53%)
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome

Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue...

ACAD : 16.82 (-1.46%)
AVXL : 3.78 (-0.53%)
APTX : 0.0960 (+3.11%)
ANVS : 10.06 (+2.13%)
Why Shares of Anavex Life Sciences Rose 12.4% in February

The company's first-quarter earnings report detailed positive news regarding its pipeline.

BIIB : 194.38 (+2.03%)
AVXL : 3.78 (-0.53%)
Is Anavex Life Sciences Stock a Buy Now?

A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.

LLY : 726.31 (-2.63%)
AVXL : 3.78 (-0.53%)
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 270.28% as Wall Street Analysts Expect?

The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 270.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

AVXL : 3.78 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 4.05
2nd Resistance Point 3.93
1st Resistance Point 3.85
Last Price 3.78
1st Support Level 3.65
2nd Support Level 3.53
3rd Support Level 3.45

See More

52-Week High 10.45
Fibonacci 61.8% 7.83
Fibonacci 50% 7.02
Fibonacci 38.2% 6.22
Last Price 3.78
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar